We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+26.89%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$233M
AUM Growth
+$19M
(+8.9%)
Cap. Flow
-$54.1M
Cap. Flow
% of AUM
-23.21%
Top 10 Holdings %
Top 10 Hldgs %
51.27%
Holding
65
New
21
Increased
9
Reduced
22
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$7.06M |
| 2 |
APTO
Aptose Biosciences, Inc.
APTO
|
+$5.61M |
| 3 |
CLLS
Cellectis
CLLS
|
+$4.21M |
| 4 |
Baxter International
BAX
|
+$3.7M |
| 5 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$3.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Iovance Biotherapeutics
IOVA
|
+$11.1M |
| 2 |
Kura Oncology
KURA
|
+$11M |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$10.6M |
| 4 |
United Therapeutics
UTHR
|
+$8.89M |
| 5 |
Direxion Daily Small Cap Bear 3x ETF
TZA
|
+$7.42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.12% |
| 2 | Miscellaneous | 13.55% |
| 3 | Technology | 3.99% |
| 4 | Energy | 0.34% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Pacira BioSciences
PCRX
$1.03B
| $2.89M | 1.24% |
+55,000
| New | +$2.3M |
|
27
Personalis
PSNL
$1.82B
| $2.45M | 1.05% |
188,750
-225,990
| -54% | -$2.51M |
|
28
Establishment Labs
ESTA
$2.11B
| $2.38M | 1.02% |
127,173
+515
| +0.4% | +$8.76K |
|
29
Immunovant
IMVT
$8.51B
| $2.33M | 1% |
95,500
-25,929
| -21% | -$556K |
|
30
Organogenesis Holdings
ORGO
$224M
| $2.06M | 0.88% |
535,616
-136,659
| -20% | -$493K |
|
31
Encompass Health
EHC
$11.9B
| $2.04M | 0.87% |
41,355
-17,598
| -30% | -$950K |
|
|
32
United Therapeutics
UTHR
$22.1B
| $1.81M | 0.78% |
15,000
-79,000
| -84% | -$8.89M |
|
|
TPTX
33
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $1.65M | 0.71% |
+25,602
| New | +$1.48M |
|
|
TBIO
34
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $1.6M | 0.69% |
+89,510
| New | +$1.35M |
|
35
Aurinia Pharmaceuticals
AUPH
$2.17B
| $1.5M | 0.64% |
+92,000
| New | +$1.47M |
|
36
Evolus
EOLS
$587M
| $1.49M | 0.64% |
281,541
-232,665
| -45% | -$1.07M |
|
|
TVRD
37
Tvardi Therapeutics
TVRD
$24.3M
| $1.49M | 0.64% |
+2,416
| New | +$1.33M |
|
38
Gyre Therapeutics
GYRE
$699M
| $1.46M | 0.63% |
33,073
-17,980
| -35% | -$844K |
|
39
Dianthus Therapeutics
DNTH
$5.92B
| $1.27M | 0.54% |
+10,536
| New | +$1.48M |
|
40
AMN Healthcare
AMN
$1.34B
| $1.22M | 0.52% |
26,851
-56,620
| -68% | -$2.71M |
|
41
NeoGenomics
NEO
$2.32B
| $1.2M | 0.52% |
+38,819
| New | +$1.08M |
|
|
MODV
42
DELISTED
ModivCare
MODV
| $1.18M | 0.51% |
+14,923
| New | +$1.01M |
|
|
EVFM
43
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
| $1.17M | 0.5% |
+27,519
| New | +$1.85M |
|
|
BEAT
44
DELISTED
BioTelemetry, Inc.
BEAT
| $1.12M | 0.48% |
+24,733
| New | +$1.11M |
|
45
Xeris Biopharma Holdings
XERS
$1.55B
| $1.12M | 0.48% |
+419,469
| New | +$1.46M |
|
|
LHCG
46
DELISTED
LHC Group LLC
LHCG
| $786K | 0.34% |
4,509
-30,400
| -87% | -$4.46M |
|
|
APEN
47
DELISTED
Apollo Endosurgery, Inc.
APEN
| $621K | 0.27% |
379,945
+42,683
| +13% | +$84.8K |
|
|
MITO
48
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
| $533K | 0.23% |
291,144
-45,023
| -13% | -$82K |
|
|
MGLN
49
DELISTED
Magellan Health Services, Inc.
MGLN
| $379K | 0.16% |
+5,200
| New | +$333K |
|
|
ONEM
50
PUT
DELISTED
1Life Healthcare
ONEM
| $291K | 0.12% |
+8,000
| New | +$225K |
|
Similar funds
SC
CCWM
CMA
RIS
MFS
GFI
PWM
CA
Prosight Management's Q2 2020 Portfolio in Review
As of Q2 2020, Prosight Management held 65 positions worth $233M, up 8.9% from $214M the previous quarter. Its ten largest holdings account for 51% of the portfolio.
Prosight Management withdrew a net $54.1M in Q2 2020, closing 13 positions and reducing 22 holdings. Its most notable exit was Direxion Daily Small Cap Bear 3x ETF, an estimated $7.42M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 91% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, Prosight Management opened a new position in Bristol-Myers Squibb worth $6.94M.
- Prosight Management's largest Q2 2020 buy was Bristol-Myers Squibb: 118,000 shares worth $6.94M.
- Prosight Management added most to Change Healthcare Inc. Common Stock in Q2 2020, an estimated $3.04M increase.
- Prosight Management's biggest Q2 2020 reduction was Iovance Biotherapeutics, cutting an estimated $11.1M.
- Prosight Management fully exited Direxion Daily Small Cap Bear 3x ETF in Q2 2020, selling an estimated $7.42M.
- Prosight Management's ten largest holdings make up 51% of its $233M portfolio in Q2 2020.
- Prosight Management opened 21 new positions and closed 13 in Q2 2020.
- Prosight Management's portfolio value rose 8.9% quarter-over-quarter to $233M.
Based on Prosight Management's 13F filing for Q2 2020, filed 14 Aug 2020.